Balaji Gandhi Sells 8,009 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 8,009 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $136,233.09. Following the sale, the chief financial officer directly owned 156,231 shares of the company’s stock, valued at $2,657,489.31. The trade was a 4.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Friday, October 17th, Balaji Gandhi sold 885 shares of Phreesia stock. The shares were sold at an average price of $22.36, for a total transaction of $19,788.60.

Phreesia Stock Down 3.4%

Shares of PHR stock opened at $16.55 on Wednesday. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. Phreesia, Inc. has a 12 month low of $15.41 and a 12 month high of $32.76. The stock has a market cap of $998.04 million, a P/E ratio of -165.52 and a beta of 0.61. The company has a 50 day simple moving average of $18.72 and a two-hundred day simple moving average of $23.53.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. The firm had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The company’s revenue for the quarter was up 12.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.25) EPS. On average, research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Latest reported quarter showed revenue and EPS upside (revenue $120.3M, EPS $0.10 vs. consensus ~($0.01)), which supports the company’s growth story and could cap downside after the sell‑off. MarketBeat: Phreesia earnings summary
• Neutral Sentiment: Royal Bank of Canada initiated coverage on PHR this week — initiations often boost visibility and trading volume but don’t always change consensus direction immediately. RBC initiates coverage on Phreesia
• Negative Sentiment: Citigroup cut its price target on PHR to $25 (from $29), reducing upside expectations from a widely followed sell‑side shop; such changes can pressure sentiment among investors tracking analyst targets. Citigroup cuts Phreesia price target to $25
• Negative Sentiment: Multiple senior insiders sold shares on Jan. 8 (CFO Balaji Gandhi, General Counsel Allison Hoffman, EVP/other officers including Amy Beth Vanduyn, Evan Roberts and David Linetsky). Collective Form 4 filings show routine but sizable sales around ~$17/share, which increases float and can be read as reduced near‑term insider conviction. Insider selling report

Wall Street Analyst Weigh In

PHR has been the topic of a number of analyst reports. Truist Financial set a $24.00 price objective on Phreesia in a research report on Thursday, January 8th. BMO Capital Markets started coverage on shares of Phreesia in a report on Thursday, November 13th. They set an “outperform” rating and a $32.00 price target on the stock. Barclays reduced their price objective on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, December 16th. Zacks Research cut shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Citigroup cut their price target on Phreesia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, January 9th. Seventeen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.06.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Federated Hermes Inc. bought a new stake in shares of Phreesia in the third quarter worth about $32,000. Asset Management One Co. Ltd. purchased a new position in Phreesia during the 3rd quarter valued at approximately $45,000. State of Alaska Department of Revenue purchased a new position in Phreesia during the 3rd quarter valued at approximately $83,000. Farther Finance Advisors LLC increased its stake in Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock worth $86,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Anchor Investment Management LLC purchased a new stake in shares of Phreesia during the 3rd quarter worth approximately $118,000. Institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.